Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKinsey
Colorcon
Medtronic
Boehringer Ingelheim

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022497

See Plans and Pricing

« Back to Dashboard

NDA 022497 describes FORFIVO XL, which is a drug marketed by Alvogen and is included in one NDA. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the FORFIVO XL profile page.

The generic ingredient in FORFIVO XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Summary for 022497
Tradename:FORFIVO XL
Applicant:Alvogen
Ingredient:bupropion hydrochloride
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022497
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FORFIVO XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 022497 NDA AUTHORIZED GENERIC Alvogen Inc. 47781-637 47781-637-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (47781-637-30)
FORFIVO XL bupropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 022497 NDA Edgemont Pharmaceuticals, LLC 49909-010 49909-010-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (49909-010-30)
Paragraph IV (Patent) Challenges for 022497
Tradename Dosage Ingredient NDA Submissiondate
FORFIVO XL TABLET, EXTENDED RELEASE;ORAL bupropion hydrochloride 022497 2013-02-28

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength450MG
Approval Date:Nov 10, 2011TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 25, 2027Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Merck
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.